However, it is important to note that many previous studies were conducted in a CV diabetic cohort and before the widespread use of renin–angiotensin system (RAS) blockers and statins or the advent of glucose-lowering drugs such as sodium-glucose co-transporter-2 inhibitors (SGLT2-i) or glucagon-like peptide-1 receptor analog (GLP1-RA) that modify risk of ischemic heart disease (IHD) and HF. The gene discussed is SLC5A2; the disease is hydrops fetalis.